For the quarter ending 2025-11-30.
| Income Statement | 2025-11-30 | 2025-08-31 | 2025-05-31 | 2024-11-30 |
|---|---|---|---|---|
| Revenue | 0 | 169,038.5* | 174,000 | 183,923 |
| Cost of goods sold | 0 | -1,360* | 0 | 2,720 |
| Gross profit | 0 | 170,398.5* | 174,000 | 181,203 |
| Research and development | 671,340 | 1,269,071.5* | 2,717,501 | 1,953,220 |
| General and administrative | 902,291 | 1,156,768* | 1,206,920 | 918,690 |
| Total operating expenses | 1,573,631 | 2,425,839.5* | 3,924,421 | 2,871,910 |
| Loss from operations | -1,573,631 | -2,255,441* | -3,750,421 | -2,690,707 |
| Interest income | 12 | 2,715.5* | 190 | 11 |
| Unrealized gain on marketable securities | -22,093 | 87,142.5* | -40,375 | -15,932 |
| Total other income (gain) | -22,081 | 89,858* | -40,185 | - |
| Net loss before income taxes | -1,595,712 | - | - | - |
| Other nonoperating income (expense) | - | - | - | -15,921 |
| Income taxes | 1,791 | - | - | - |
| Net loss | -1,597,503 | -2,165,583* | -3,790,606 | -2,706,628 |
| Less net loss attributable to non-controlling interest | -2,496 | -2,928.5* | -1,514 | -2,929 |
| Net loss attributable to lexaria shareholders | -1,595,007 | -2,162,654.5* | -3,789,092 | -2,703,699 |
| Foreign currency translation adjustment | -5,744 | -101,516* | 37,173 | -3,175 |
| Total comprehensive loss | -1,600,751 | -2,264,170.5 | -3,751,919 | -2,706,874 |
| Diluted EPS | -0.07 | -0.119 | -0.21 | -0.16 |
| Diluted Average Shares | 21,376,029 | 19,029,323 | 18,298,309 | 16,668,513 |
Lexaria Bioscience Corp. (LEXX)
Lexaria Bioscience Corp. (LEXX)